MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs ...

Metsera cleared that benchmark Monday, with a jump from 78 to 82 Monday. Please watch the video at Investors.com - How To ...

We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where ...

So far this year, 11 U.S. venture-backed private companies have gone public or agreed to be acquired at valuations of $1 ...

Metsera (NASDAQ:MTSR) was able to complete its initial public offering [IPO] back on February 3rd of 2025. Before taking expenses into account, it was able to generate net proceeds of about $316.2 ...

BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage biotech breaking into the obesity market, the analyst ...

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside.

Metsera Inc. MTSR, a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in ...

Metsera’s (NASDAQ:MTSR – Get Free Report) quiet period is set to expire on Wednesday, March 12th. Metsera had issued 15,277,778 shares in its initial public offering on January 31st. The total ...

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to ...

Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates. The bank highlighted Metsera's (NASDAQ:MTSR) long-acting GLP-1RA asset ...